Page 5 - Raf And Mek Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dan calkinsElisa buffingtonDan patersonQiang luRyan porterRaf and mek programDrug administrationCorporate communicationsCompany annual report on formDevelopment expertiseSecura bio incExchange commissionChugai pharmaceutical co ltdSynergistic collaboration basedVerastem oncologyGenfleet therapeutic discovery capabilities

Verastem Oncology (VSTM) Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

Verastem Oncology (VSTM) Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dan calkinsRyan porterElisa buffingtonDan patersonQiang luSecura bio incExchange commissionChugai pharmaceutical co ltdCompany annual report on formDrug administrationCorporate communicationsRaf and mek programVerastem oncologyGenfleet therapeuticsChief executive officerBreakthrough therapy

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progre

Presented Positive Results from Part A of RAMP 201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) at American Society of Clinical Oncology MeetingEstablished Design for RAMP 301 Phase 3 Confirmatory Trial of Avutometinib and Defactinib in Recurrent LGSOCStrengthened Balance.

United statesDan calkinsKarin tollefsonDan patersonRobert gagnonBrian stuglikElisa buffingtonNate liabraatenCompany board of directorsRaf and mek programCommercialization committeeAmerican society of clinical oncology meetingCorporate communicationsCompany phaseEuropean network of gynaecological oncological trialExchange commission

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

Brian Stuglik to Retire from CEO Role; Continue to Serve on Company’s Board of Directors

Michael kauffmanBrian stuglikDan patersonCommercialization committeeDrug administrationSecura bio incChugai pharmaceutical co ltdCompany annual report on formExchange commissionRaf and mek programVerastem oncologyChief operating officerChief executive officerBreakthrough therapy designationBreakthrough therapySecura bio

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurren

Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination.

United statesCity ofUnited kingdomDan calkinsElisa buffingtonBrian stuglikNate liabraatenRachel grishamSusana banerjeeNational cancer instituteInstitute of cancer researchEuropean society of gynaecological oncologyPartners programCorporate communicationsChugai pharmaceutical co ltdDrug administration